Several chimeric antigen receptor (CAR)-T cell therapy clinical trials have been launched to target glioblastoma-associated surface antigens, e.g., IL13Rα2, HER2 and GD2, with fewer focusing on the glioblastoma-specific but subclonal antigen, EGFRvIII10,11. The gene discussed is IL13RA2; the disease is glioblastoma.